[1]倪文婧,徐书杭,刘超.2021年美国甲状腺学会关于甲状腺未分化癌管理指南解读:实践精准医学[J].国际内分泌代谢杂志,2022,42(02):161-164.[doi:10.3760/cma.j.cn121383-20211101-11002]
　Ni Wenjing,Xu Shuhang,Liu Chao..Interpretation of 2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer: era of individualized precision medicine[J].International Journal of Endocrinology and Metabolism,2022,42(02):161-164.[doi:10.3760/cma.j.cn121383-20211101-11002]
点击复制

2021年美国甲状腺学会关于甲状腺未分化癌管理指南解读:实践精准医学()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
42
期数:
2022年02期
页码:
161-164
栏目:
指南与共识
出版日期:
2022-03-20

文章信息/Info

Title:
Interpretation of 2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer: era of individualized precision medicine
作者:
倪文婧; 徐书杭; 刘超
南京中医药大学附属中西医结合医院内分泌科 210028
Author(s):
Ni Wenjing;  Xu Shuhang;  Liu Chao.
Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China
关键词:
甲状腺未分化癌;  分子检测;  靶向治疗;  精准医学
Keywords:
Anaplastic thyroid cancer;  Molecular testing;  Targeted therapy;  Precision medicine
DOI:
10.3760/cma.j.cn121383-20211101-11002
摘要:
2021年,美国甲状腺学会(ATA)更新了《甲状腺未分化癌患者的管理指南》,共包含31条推荐和16条良好实践声明。基于既往十余年临床研究成果,新版指南突出强调分子检测及靶向治疗的地位,并初步肯定免疫治疗的临床价值。甲状腺未分化癌(ATC)的管理已然迈入个体化的精准诊疗时代。本文通过解读新版指南要点,指出目前ATC诊疗中获得的巨大进步和依然存在的问题,以帮助临床医师在多学科团队协作下,进一步提升ATC的诊疗能力。
Abstract:
In 2021, American Thyroid Association(ATA)updated guideline for management of patients with anaplastic thyroid cancer(ATC), which entails 31 recommendations and 16 good practice statements. With substantial improvement of clinical research during last decade, the new guideline put a high value of molecular testing, targeted therapy and recognized the clinic value of immunotherapy in ATC management. ATC management has entered the era of individualized precision medicine. In a way that interpreting the highlights of the new guideline, we confirm the great progress in current ATC diagnosis and treatment as well as point out some unresolved problems, aiming to attain multidisciplinary team engagement and coordination so as to help clinicians further improve the management of ATC.

参考文献/References:

[1] Smallridge RC,Ain KB,Asa SL,et al.American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer[J].Thyroid,2012,22(11):1104-1139.DOI:10.1089/thy.2012.0302.
[2] Bible KC,Kebebew E,Brierley J,et al.2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer[J].Thyroid,2021,31(3):337-386.DOI:10.1089/thy.2020.0944.
[3] Ljubas J,Ovesen T,Rusan M.A systematic review of phase II targeted therapy clinical trials in anaplastic thyroid cancer[J].Cancers(Basel),2019,11(7):943.DOI:10.3390/cancers11070943.
[4] Qin Y,Wang JR,Wang Y,et al.Clinical utility of circulating cell-free DNA mutations in anaplastic thyroid carcinoma[J].Thyroid,2021,31(8):1235-1243.DOI:10.1089/thy.2020.0296.
[5] Park J,Jung HA,Shim JH,et al.Multimodal treatments and outcomes for anaplastic thyroid cancer before and after tyrosine kinase inhibitor therapy:a real-world experience[J].Eur J Endocrinol,2021,184(6):837-845.DOI:10.1530/EJE-20-1482.
[6] Subbiah V,Baik C,Kirkwood JM.Clinical development of BRAF plus MEK inhibitor combinations[J].Trends Cancer,2020,6(9):797-810.DOI:10.1016/j.trecan.2020.05.009.
[7] Wang JR,Zafereo ME,Dadu R,et al.Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma[J].Thyroid,2019,29(8):1036-1043.DOI:10.1089/thy.2019.0133.
[8] Cantara S,Bertelli E,Occhini R,et al.Blockade of the programmed death ligand 1(PD-L1)as potential therapy for anaplastic thyroid cancer[J].Endocrine,2019,64(1):122-129.DOI:10.1007/s12020-019-01865-5.
[9] Bastman JJ,Serracino HS,Zhu Y,et al.Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer[J].J Clin Endocrinol Metab,2016,101(7):2863-2873.DOI:10.1210/jc.2015-4227.
[10] Capdevila J,Wirth LJ,Ernst T,et al.PD-1 blockade in anaplastic thyroid carcinoma[J].J Clin Oncol,2020,38(23):2620-2627.DOI:10.1200/JCO.19.02727.
[11] König IR,Fuchs O,Hansen G,et al.What is precision medicine?[J].Eur Respir J,2017,50(4):1700391.DOI:10.1183/13993003.00391-2017.
[12] Cabanillas ME,Dadu R,Iyer P,et al.Acquired secondary RAS mutation in BRAFV600E-mutated thyroid cancer patients treated with BRAF inhibitors[J].Thyroid,2020,30(9):1288-1296.DOI:10.1089/thy.2019.0514.

相似文献/References:

[1]李兴佳,郑全喜,陈国芳,等.七叶皂苷钠抑制人甲状腺未分化癌HTh74 细胞株增殖作用的研究[J].国际内分泌代谢杂志,2016,36(02):116.[doi:10.3760/cma.j.issn.1673-4157.2016.02.010]
　Li Xingjia,Zheng Quanxi,Chen Guofang,et al.Inhibitory effects of sodium aescinate on cell proliferation in human anaplastic thyroid carcinoma cell HTh74[J].International Journal of Endocrinology and Metabolism,2016,36(02):116.[doi:10.3760/cma.j.issn.1673-4157.2016.02.010]

备注/Memo

备注/Memo:
通信作者:徐书杭,Email:shuhangxu@163.com
基金项目:江苏省卫生健康委2020年度医学科研项目(面上项目,M2020102); 2020年江苏省重点研发计划(社会发展,BE2020726)
更新日期/Last Update: 2022-04-20